Integrated DNA Technologies (IDT), a global genomics company, has released a new tool designed to improve the accuracy of CRISPR-based gene editing.
The Alt-R HDR Enhancer Protein helps cells repair DNA in a more precise way, doubling the efficiency of a process known as homology-directed repair, or HDR, in hard-to-edit cells such as induced pluripotent stem cells and hematopoietic and progenitor stem cells. The protein preserves cell health and genomic stability while avoiding unwanted edits.
Produced by Aldevron, a fellow Danaher company, the protein meets rigorous manufacturing standards for quality and consistency, IDT officials say.
“IDT’s legacy of innovation, market leadership in CRISPR and strong collaborations with gene editing pioneers enabled us to develop a first-to-market Alt-R HDR Enhancer Protein that delivers on our customers’ therapeutic research needs and desire to fast-track breakthroughs,” said Sandy Ottensmann, vice president and general manager of Gene Writing and Editing at IDT. “It’s exciting to see from early access users that this pathway specific, protein-based enhancer shifts the DNA repair pathway balance toward HDR, promoting more precise genome modification without compromising cell viability or genomic integrity, demonstrating its scalability in therapeutic development applications.”
CRISPR is widely used for disabling genes, a process known as knockout editing, but inserting or correcting genes through HDR is more difficult. Early studies with IDT’s Alt-R HDR Enhancer Protein show a measurable increase in HDR success across different genes and cell types, suggesting the enhancer could become a standard tool for researchers working on next-generation therapies.
The protein is initially available for research use in 500 μg and 5 mg formats, with a clinical-grade version in development. It is compatible with different CRISPR enzymes and delivery systems, allowing it to fit into existing workflows.
IDT’s full CRISPR portfolio includes optimized Cas9 and Cas12a enzymes, customizable guide RNAs, HDR solutions, manufacturing services and analysis tools. Together, these have supported scientific advances, including the development of the world’s first personalized CRISPR therapy.
More information is available at www.idtdna.com/HDREnhancerProtein.
